Table 2.

Concentrations (median, interquartile range) of circulating anti-LPS, LBP, α-1AGP, and CRP in different groups. All comparisons are between individual patient groups and healthy controls for each assay. P values < 0.05 are considered significant.

Assays	Oligoarticular JIA, n = 31	Polyarticular JIA, n = 22	SpA, n = 16	IBD-related Arthritis, n = 11	Healthy Controls, n = 34
Anticore LPS, EIA units, n = 112^*, IQR	333	471	415	318	239
Anticore LPS, EIA units, n = 112^*, IQR	227–472	263–676	303–771	216–398	143–325
p value vs controls	0.024	< 0.001	0.001	0.111	NA
LBP, ng/ml, n = 112^* IQR	9.4	18.7	13.5	11.8	5.3
LBP, ng/ml, n = 112^* IQR	4.3–22.9	9.4–34.7	6.7–14.7	3.6–17.9	1.8–9.0
p value vs controls	0.002	0.001	0.006	0.108	NA
α-1AGP, μg/ml, n = 114 IQR	1203	1398	1116	759	658
α-1AGP, μg/ml, n = 114 IQR	820–1468	1025–1843	760–13,867	630–991	523–908
p value vs controls	0.001	0.001	0.003	0.185	NA
CRP, μg/ml, n = 107^* IQR	2.4	12.3	2.1	0.9	0.07
CRP, μg/ml, n = 107^* IQR	0.6–4.2	1.1–64.2	0.3–4.5	0–4.1	0–0.7
p value vs controls	0.001	< 0.001	0.001	0.122	NA

↵* For some subjects, we had insufficient serum or plasma to perform all EIA, so n for some assays does not always equal 114. LPS: lipopolysaccharide; LBP: LPS-binding protein; α-1AGP: α-1-acid glycoprotein; CRP: C-reactive protein; JIA: juvenile idiopathic arthritis; SpA: spondyloarthropathies; EIA: enzyme immunoassay; IBD: inflammatory bowel disease; NA: not applicable.